Targeting PDE6D for inhibiting KRAS: A computational approach

23 November 2022, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Lung cancer is the cancer of the lung's epithelial cells typically characterized by difficult breathing, chest pain, blood-stained coughs, headache, and weight loss. If left unmanaged, lung cancer can spread to other body parts. While several treatment methods exist for managing lung cancer, exploring natural plant sources for developing therapeutics offers great potential in complementing different treatment approaches. Several efforts have focused on inhibiting specific mutated genes, including Epidermal Growth Factor Receptors and Anaplastic Lymphoma Kinase implicated in lung cancer. In this study, we concentrated on inhibiting the mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) by targeting an associated protein (Phosphodiesterase 6δ) to which KRAS form complexes. We evaluated bioactive compounds from Lingonberry (Vaccinium vitis-idaea L), adopting computational approaches such as molecular docking, molecular dynamics simulation, molecular mechanics/generalized Born surface area (MM/GBSA) calculations, and pharmacokinetics analysis. A total of 26 out of 39 bioactive compounds of Vaccinium vitis-idaea L had a higher binding affinity to the target receptor than the approved drug, Sotorasib. Further, the pharmacokinetics properties of the lead compounds were examined, and the best four compounds, namely, (+) – Catechin (Cianidanol), Arbutin, Resveratrol, and Sinapic acid, were further subjected to molecular dynamic simulation. In conclusion, Arbutin (+) – Catechin and Sinapic acid are predicted to be the best compound of Vaccinium vitis-idaea L. because of their pharmacokinetic properties and drug-likeness attributes. Also, their stability to the target receptor makes them a potential drug candidate that could be explored for treating KRAS-mutation-associated lung cancer.

Keywords

Kirsten rat sarcoma viral oncogene (KRAS)
Phosphodiesterase 6δ (PDE6D)
Lung cancer
Molecular docking
Molecular dynamic simulation
Pharmacokinetic properties

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.